Literature DB >> 25673959

Conestat alfa (ruconest): first recombinant c1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.

Martin Paspe Cruz.   

Abstract

Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.

Entities:  

Year:  2015        PMID： 25673959      PMCID： PMC4315111     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  10 in total

1.  Normal C1 inhibitor hereditary angioedema.

Authors:  Weekitt Kittisupamongkol
Journal:  Am J Med       Date:  2009-05       Impact factor: 4.965

2.  Emergency treatment of anaphylaxis.

Authors:  F Estelle R Simons
Journal:  BMJ       Date:  2008-05-24

3.  Type III hereditary angioedema: defined, but not understood.

Authors:  Allen Kaplan
Journal:  Ann Allergy Asthma Immunol       Date:  2012-09       Impact factor: 6.347

4.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema.

Authors:  Martijn B A van Doorn; Jacobus Burggraaf; Tijtje van Dam; Anke Eerenberg; Marcel Levi; Cornelis E Hack; Rik C Schoemaker; Adam F Cohen; Jan Nuijens
Journal:  J Allergy Clin Immunol       Date:  2005-08-08       Impact factor: 10.793

Review 5.  C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.

Authors:  C Caliezi; W A Wuillemin; S Zeerleder; M Redondo; B Eisele; C E Hack
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

Review 6.  Update on treatment of hereditary angioedema.

Authors:  Larisa V Buyantseva; Niti Sardana; Timothy J Craig
Journal:  Asian Pac J Allergy Immunol       Date:  2012-06       Impact factor: 2.310

7.  Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.

Authors:  Andreas Lehmann
Journal:  Expert Opin Biol Ther       Date:  2008-08       Impact factor: 4.388

Review 8.  Hereditary angioedema: a current state-of-the-art review, VIII: current status of emerging therapies.

Authors:  Jonathan A Bernstein
Journal:  Ann Allergy Asthma Immunol       Date:  2008-01       Impact factor: 6.347

9.  Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor.

Authors:  Konrad Bork
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

10.  Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema.

Authors:  Paweł Kawalec; Przemysław Holko; Anna Paszulewicz
Journal:  Postepy Dermatol Alergol       Date:  2013-06-20       Impact factor: 1.837
  10 in total
  9 in total

1.  Complement Blockade in Recipients Prevents Delayed Graft Function and Delays Antibody-mediated Rejection in a Nonhuman Primate Model of Kidney Transplantation.

Authors:  Michael J Eerhart; Jose A Reyes; Casi L Blanton; Juan S Danobeitia; Peter J Chlebeck; Laura J Zitur; Megan Springer; Erzsebet Polyak; Jennifer Coonen; Saverio Capuano; Anthony M D'Alessandro; Jose Torrealba; Edwin van Amersfoort; Yolanda Ponstein; Cees van Kooten; William Burlingham; Jeremy Sullivan; Myron Pozniak; Weixiong Zhong; Yucel Yankol; Luis A Fernandez
Journal:  Transplantation       Date:  2022-01-01       Impact factor: 5.385

Review 2.  Angioedema in the emergency department: a practical guide to differential diagnosis and management.

Authors:  Jonathan A Bernstein; Paolo Cremonesi; Thomas K Hoffmann; John Hollingsworth
Journal:  Int J Emerg Med       Date:  2017-04-13

3.  Pharmaceutical Machine Learning: Virtual High-Throughput Screens Identifying Promising and Economical Small Molecule Inhibitors of Complement Factor C1s.

Authors:  Jonathan J Chen; Lyndsey N Schmucker; Donald P Visco
Journal:  Biomolecules       Date:  2018-05-07

Review 4.  Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research.

Authors:  Stefania Nicola; Giovanni Rolla; Luisa Brussino
Journal:  Drugs Context       Date:  2019-10-02

Review 5.  Self-Management Plans in Patients with Hereditary Angioedema: Strategies, Outcomes and Integration into Clinical Care.

Authors:  Constance H Katelaris
Journal:  J Asthma Allergy       Date:  2020-04-30

Review 6.  Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target.

Authors:  Chiara Agostinis; Andrea Balduit; Alessandro Mangogna; Gabriella Zito; Federico Romano; Giuseppe Ricci; Uday Kishore; Roberta Bulla
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

7.  Evaluation of staging criteria for disposition and airway intervention in emergency department angioedema patients.

Authors:  Conor Dass; Maggie Mahaffa; Elizabeth Dang; Ronna Campbell; Zuhair Ballas; Sangil Lee
Journal:  Acute Med Surg       Date:  2021-10-26

Review 8.  Bradykinin-induced angioedema in the emergency department.

Authors:  Jacques Hébert; Jean-Nicolas Boursiquot; Hugo Chapdelaine; Benoit Laramée; Marylin Desjardins; Rémi Gagnon; Nancy Payette; Oleksandra Lepeshkina; Matthieu Vincent
Journal:  Int J Emerg Med       Date:  2022-03-26

Review 9.  Targeting complement cascade: an alternative strategy for COVID-19.

Authors:  Sureshbabu Ram Kumar Pandian; Sankarganesh Arunachalam; Venkataraman Deepak; Selvaraj Kunjiappan; Krishnan Sundar
Journal:  3 Biotech       Date:  2020-10-19       Impact factor: 2.406
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.